Form 8-K - Current report:
SEC Accession No. 0001493152-22-034828
Filing Date
2022-12-08
Accepted
2022-12-08 08:40:40
Documents
17
Period of Report
2022-12-08
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 43728
2 ex99-1.htm EX-99.1 1904
3 ex99-2.htm EX-99.2 1105
4 ex99-1_001.jpg GRAPHIC 480868
5 ex99-1_002.jpg GRAPHIC 443515
6 ex99-2_002.jpg GRAPHIC 2661019
  Complete submission text file 0001493152-22-034828.txt   5157631

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE anix-20221208.xsd EX-101.SCH 3218
8 XBRL LABEL FILE anix-20221208_lab.xml EX-101.LAB 34240
9 XBRL PRESENTATION FILE anix-20221208_pre.xml EX-101.PRE 22353
11 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3661
Mailing Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118
Business Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118 408-708-9808
Anixa Biosciences Inc (Filer) CIK: 0000715446 (see all company filings)

EIN.: 112622630 | State of Incorp.: DE | Fiscal Year End: 1031
Type: 8-K | Act: 34 | File No.: 001-37492 | Film No.: 221451484
SIC: 2834 Pharmaceutical Preparations